Profound Medical Management
Management criteria checks 3/4
Profound Medical's CEO is Arun Menawat, appointed in Aug 2016, has a tenure of 8.33 years. total yearly compensation is $889.95K, comprised of 41.6% salary and 58.4% bonuses, including company stock and options. directly owns 2.28% of the company’s shares, worth CA$7.13M. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.
Key information
Arun Menawat
Chief executive officer
US$889.9k
Total compensation
| CEO salary percentage | 41.6% |
| CEO tenure | 8.3yrs |
| CEO ownership | 2.3% |
| Management average tenure | 1.9yrs |
| Board average tenure | 3.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$890k | US$370k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$916k | US$344k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$4m | US$481k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$2m | US$1m | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$2m | US$531k | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$15m |
| Jun 30 2019 | n/a | n/a | -US$14m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$672k | US$509k | -US$15m |
| Sep 30 2018 | n/a | n/a | -US$16m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$264k | US$264k | -US$15m |
Compensation vs Market: Arun's total compensation ($USD889.95K) is about average for companies of similar size in the Canadian market ($USD726.09K).
Compensation vs Earnings: Arun's compensation has been consistent with company performance over the past year.
CEO
Arun Menawat (69 yo)
8.3yrs
Tenure
US$889,948
Compensation
Dr. Arun Swarup Menawat, Ph D., MBA, serves as an Independent Director of Firefly Neuroscience, Inc. and served as its Chairman. He serves as the Chairman at Profound Medical Corp. Dr. Menawat has been the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 8.3yrs | US$889.95k | 2.28% CA$ 7.1m | |
| President | less than a year | US$396.81k | 0.13% CA$ 408.2k | |
| Chief Financial Officer | 3.6yrs | US$669.26k | 0.19% CA$ 592.9k | |
| Investor Relations | no data | no data | no data | |
| Chief Commercial Officer | less than a year | no data | 0.054% CA$ 168.7k | |
| Assistant Corporate Controller | no data | no data | no data | |
| Software Developer | no data | no data | no data |
1.9yrs
Average Tenure
56yo
Average Age
Experienced Management: PRN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 9.5yrs | US$889.95k | 2.28% CA$ 7.1m | |
| Independent Director | 6.5yrs | US$101.96k | 0.070% CA$ 219.0k | |
| Independent Lead Director | 6.5yrs | US$102.91k | 0.28% CA$ 860.7k | |
| Independent Director | 3.8yrs | US$97.91k | 0.027% CA$ 85.2k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2.6yrs | US$96.96k | no data | |
| Independent Director | 4.1yrs | US$100.41k | 0.013% CA$ 39.9k | |
| Member of Clinical Advisory Board | 2.2yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 2.2yrs | no data | no data | |
| Member of Clinical Advisory Board | 2.2yrs | no data | no data |
3.8yrs
Average Tenure
65yo
Average Age
Experienced Board: PRN's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Profound Medical Corp. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | Beacon Securities Limited |
| Jason Mills | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |